Alpha-L-Fucosidase Serves as a Prognostic Indicator for Intrahepatic Cholangiocarcinoma and Inhibits Its Invasion Capacity

Zeyu Shuang, Yize Mao, Guohe Lin, Jun Wang, Xin Huang, Jianlin Chen, Fangting Duan, and Shengping Li

1 State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China
2 Department of Breast Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China
3 Department of Hepatobiliary Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China
4 Department of Oncology, Second Affiliated Hospital of Anhui Medical University, Anhui 230000, China
5 Department of Experimental Research, Sun Yat-sen University Cancer Center, Guangzhou 510060, China

Correspondence should be addressed to Shengping Li; lishp@sysucc.org.cn

Received 3 July 2017; Accepted 29 January 2018; Published 22 February 2018

Copyright © 2018 Zeyu Shuang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Alpha-L-fucosidase (AFU), a liposomal enzyme that participates in the degradation of various fucose-containing fucoglycoconjugates has been used as a tumor marker in the diagnosis of hepatic carcinoma and colorectal cancer [8, 9]. A recent study showed that high AFU levels in serum were associated with poor outcomes in hepatocellular carcinoma [10], having a negative effect on the prognosis of patients with this type of cancer. However, possibly due to tumor heterogeneity, some studies have shown that higher AFU levels were associated with better outcomes in breast cancer [11, 12]. Higher invasion capacity is usually a cause of poor prognosis in cancer [13].

Matrix metalloproteinase 9 (MMP-9), an enzyme that degrades collagen IV to destroy basement membrane, has been shown to promote tumor invasion [14]. A recent study showed that AFU decreased the invasion of human breast cancer cells by downregulating MMP-9, which may partially explain the correlation between lower levels of AFU and poor prognosis in breast cancer.

1. Introduction

Intrahepatic cholangiocarcinoma (iCCA) is a rare but aggressive malignancy arising from the epithelium of biliary ducts [1], accounting for 5% to 30% of all primary liver malignancies [2–5]. Complete surgical resection was believed to be the best hope for cure [6]. However, even if patients are eligible for curative hepatectomy, the prognosis of iCCA is poor, with a 5-year survival rate of 22% to 31% [6, 7]. Therefore, it is important to highlight predictive factors in patients with iCCA, which may help to guide appropriate clinical management and prolong patients' survival time.

Alpha-L-fucosidase (AFU), a liposomal enzyme that participates in the degradation of various fucose-containing fucoglycoconjugates has been used as a tumor marker in the
prognosis in breast cancer [11]. As described above, AFU levels have shown different effects on outcome in different cancers; however, the prognostic significance of serum AFU levels has not so far been explored in iCCA.

In this study, we determined the best cutoff value for the preoperative AFU level and evaluated the association of AFU level with clinical outcome in patients with iCCA. In addition, we also explored the function of AFU on the invasion capacity of an iCCA cell line.

**2. Materials and Methods**

2.1. Study Population. This retrospective study was conducted on a primary cohort of the patients with histologically confirmed iCCA. All patients underwent surgery between August 1, 1999, and August 1, 2014, in the Sun Yat-sen University Cancer Center (Guangdong, China). Follow-up evaluations were performed every 3 months during the first 5 years and annually thereafter. This retrospective study was approved by the Institutional Review Board (IRB) of the Sun Yat-sen University Cancer Center.

2.2. Clinical Data Collection. All of the clinical and pathological information was collected from medical records at the Sun Yat-sen University Cancer Center. Clinicopathological data included age, sex, lymph node metastasis, tumor number, tumor size, and TNM stage. The tumor stage was determined according to the 7th TNM staging system established by the Union for International Cancer Control and the American Joint Committee on Cancer (AJCC) [15]. Laboratory data including ALT, AST, AFU, and CA19-9 were collected from the preoperative examinations. The serum AFU activity was detected by 7600 Clinical Analyzer obtained from Hitachi High-Technologies (Tokyo, Japan) as previously described [16]. Overall survival (OS) was defined as the time (in months) between the date of surgery and the date of the death.

2.3. Cell Culture. The human iCCA cell line HuH28 was obtained from RIKEN (Saitama, Japan), maintained in a 37°C humidified incubator, and cultured in Roswell Park Memorial Institute (RPMI) 1640 (Invitrogen Corp., USA) supplemented with 10% heat-inactivated fetal bovine serum (Gibco-BRL, Carlsbad, California, USA).

2.4. AFU Treatment. AFU (Sigma-Aldrich, St. Louis, Missouri, USA) was diluted in sterile phosphate-buffered saline (PBS) to a concentration of 1.69 mU/mL (8.8 mU/10⁶ cells) as described previously [11]. After being mixed with AFU (8.8 mU AFU/10⁶ cells), the HuH28 cell line was incubated at 37°C for 30 minutes. In parallel, the same number of cells was treated with PBS or AFU plus 1 nM deoxyfuconojirimycin (DFJ; Enzo Life Sciences, New York, New York, USA) and simultaneously incubated at 37°C for 30 minutes. Cells were finally washed with PBS and centrifuged to remove any residual AFU or DFJ.

2.5. Protein Extraction, Western Blot, and Antibodies. Following treatment with PBS/AFU/AFU + DFJ for 30 minutes as described above, protein was extracted from the HuH28 cells. Protein lysates were prepared with radioimmunoprecipitation assay (RIPA) buffer (Cell Signaling Technology, Danvers, USA) supplemented with 1 mM of phenylmethanesulfonyl fluoride (Sigma-Aldrich, USA) as recommended.

For the Western blot, a volume of extract equivalent to 15 μg of total protein was run in each lane. The antibodies used were antibody against MMP-9 (Cell Signaling Technology; 1:500), antibody against MMP-2 (Merck Millipore, Bedford, USA; 1:500), and antibody against α-tubulin (Santa Cruz Biotechnology, Santa Cruz, USA; 1:5000).

2.6. Cell Invasion Assay. The invasion assays were conducted using Matrigel Invasion chambers (8 μm; Corning BioCoat, Cambridge, Massachusetts, USA) according to the manufacturer's instructions. Briefly, after being treated with PBS/AFU/AFU + DFJ for 30 minutes as described above, the cells were resuspended in serum-free medium to a final concentration of 7×10⁵/mL. The cell suspension (200 μL) was then pipetted into the top chamber. Medium (800 μL) with 10% fetal bovine serum was added to the lower chamber as a chemoattractant. After a 24-hour incubation, the cells on the upper side of the membrane were mechanically removed with cotton swabs, and cells that had migrated to the lower surface were fixed with 100% methanol and stained with 0.1% crystal violet. The cells were counted in five fields of triplicate membranes at ×100 magnification using an Olympus IX71 microscope.

2.7. Cell Viability. To assess cell viability, cells were trypsinized, resuspended in PBS, and counted, before subsets were treated with PBS/AFU/AFU + DFJ as described. A volume of 100 μL of medium containing 2×10³ cells/well was then plated onto a 96-well culture plate. At 24 hours after treatment, a Cell Counting Kit-8 (CCK8) assay was performed. For the latter, 10 μL CCK-8 solution (Dojindo, Kumamoto, Japan) was added to each well and incubated at 37°C with 5% CO₂ for 2.5 hours. The optical density, after calibration, was read with a microplate reader (Bio-Rad, La Jolla, USA) at 450 nm. The experiments were repeated for a minimum of three times.

2.8. Statistical Analyses. The optimal cutoff values for AFU were determined using a receiver operating characteristic (ROC) curve. The cutoff value that was chosen was the level where the score was closest to the point with both maximum sensitivity and specificity. The AFU values were categorized into two groups: <20.85 U/L and ≥20.85 U/L.

For continuous variables, the data were expressed as mean ± standard deviation (SD) and compared by Student's t-test (two-sided). Categorical variables were compared using the χ² test or Fisher's exact test where appropriate. The Cox proportional hazards model was used for univariate and multivariate analyses. By the Kaplan-Meier method, patients' clinical endpoints were calculated and compared using the log-rank test. All of the factors entered into a multivariate analysis had a P value < 0.05 on univariate analysis. Hazard ratios (HRs) and their corresponding 95% confidence intervals (CIs) were estimated by Cox regression analysis.
3. Results

3.1. Patients. A total of 165 patients with iCCA were enrolled, with 148 patients being included in the analysis and 17 patients being excluded for incomplete preoperative laboratory data \( (n = 10) \) or follow-up after surgery of <3 months \( (n = 7) \).

3.2. ROC Analysis of AFU. In the present study, we used ROC curve analysis for survival prediction to verify the optimal cutoff points for AFU (Figure 1). The results indicated that a serum AFU value of 20.85 U/L had the most significant predictive value on OS. The patients were therefore divided into two main groups using this optimal cutoff level for AFU. The clinicopathological characteristics of the patients are detailed in Table 1. There were 65 patients (43.9%) with an AFU level < 20.85 U/L and 83 patients (56.1%) with a level ≥ 20.85 U/L. The \( \chi^2 \) test revealed that there were no significant differences between the two groups.

3.3. Univariate and Multivariate Analyses of AFU as an Independent Prognostic Factor for OS. Univariate and multivariate analyses were performed to explore the significance of AFU level on the prognosis of patients with iCCA. The results of the Cox regression hazards model for predictors of OS are shown in Table 2.

Univariate analysis showed that lymph node metastasis \( (HR = 2.746; 95\% CI = 1.744–4.323; P < 0.001) \), tumor number \( (HR = 5.236; 95\% CI = 3.194–8.689; P = 0.006) \), tumor size \( (HR = 2.210; 95\% CI = 1.364–3.581; P = 0.001) \), TNM stage \( (HR = 3.542; 95\% CI = 1.983–6.328; P < 0.001) \), AFU \( (HR = 0.596; 95\% CI = 0.381–0.932; P = 0.023) \), and CA19-9 \( (HR = 2.793, 95\% CI = 1.786–4.368; P < 0.001) \) were associated with OS.

On multivariate analysis, lymph node metastasis \( (HR = 2.407; 95\% CI = 1.435–4.037; P = 0.001) \), AFU \( (HR = 0.526; 95\% CI = 0.331–0.834; P = 0.006) \), TNM stage \( (HR = 2.677; 95\% CI = 1.418–5.053; P = 0.002) \), and CA19-9 \( (HR = 2.778, 95\% CI = 1.748–4.412; P < 0.001) \) were predictors of OS.

In summary, on univariate analysis, an elevated preoperative level of AFU was significantly associated with prolonged OS and remained significant in the multivariate analysis. Moreover, patients with an AFU level of <20.85 U/L showed a median OS of 20.1 months, whereas patients with an AFU level of ≥20.85 U/L had a median OS of 44.3 months \( (P = 0.022; \) Figure 2).
Table 1: Relationship between clinicopathological characteristics and serum alpha-L-fucosidase (AFU) level in 148 patients with intrahepatic cholangiocarcinoma (iCCA).

| Variables                  | Number | <20.85 | ≥20.85 | P value |
|----------------------------|--------|--------|--------|---------|
| Age (years)                |        |        |        |         |
| <60                        | 91     | 45 (69.2) | 46 (55.4) | 0.087   |
| ≥60                        | 57     | 20 (30.8) | 37 (44.6) |         |
| Sex                        |        |        |        |         |
| Female                     | 54     | 23 (35.4) | 31 (37.3) | 0.623   |
| Male                       | 94     | 42 (64.6) | 52 (62.7) |         |
| Lymph node metastasis      |        |        |        |         |
| No                         | 105    | 47 (72.3) | 58 (69.9) | 0.747   |
| Yes                        | 43     | 18 (27.7) | 25 (30.1) |         |
| Tumor number               |        |        |        |         |
| Solitary                   | 95     | 41 (63.1) | 54 (65.1) | 0.803   |
| Multiple                   | 53     | 24 (36.9) | 29 (34.9) |         |
| ALT (U/L)                  |        |        |        |         |
| ≤40                        | 112    | 51 (78.5) | 61 (73.5) | 0.485   |
| >40                        | 36     | 14 (21.5) | 22 (26.5) |         |
| AST (U/L)                  |        |        |        |         |
| ≤45                        | 132    | 61 (93.8) | 71 (85.5) | 0.106   |
| >45                        | 16     | 4 (6.2)  | 12 (14.5) |         |
| Tumor size (cm)            |        |        |        |         |
| ≤5                         | 57     | 23 (35.4) | 34 (41) | 0.489   |
| >5                         | 91     | 42 (64.6) | 49 (59) |         |
| TNM stage                  |        |        |        |         |
| I                          | 46     | 24 (36.9) | 22 (26.5) | 0.174   |
| II–IV                      | 102    | 41 (63.1) | 61 (73.5) |         |
| CA19-9 (U/mL)              |        |        |        |         |
| <100                       | 94     | 40 (61.5) | 54 (65.1) | 0.659   |
| ≥100                       | 54     | 25 (38.5) | 29 (34.9) |         |

As expected, exogenous AFU decreased the invasion ability of iCCA cells, as indicated by the decreased number of migrated cells (Figure 3), but this effect of AFU was almost completely blocked by DFJ. Moreover, to exclude interference from the AFU on the number of cells, we performed a CCK8 assay. Our results showed that AFU did not inhibit proliferation of the HuH28 cells (Supplementary Figure 1). These results suggest that AFU may weaken the invasive abilities of iCCA cells.

3.5. AFU Decreased the Invasion Ability of iCCA Cells by Decreasing the Expression of MMP-2 and MMP-9. To explore the mechanism by which AFU inhibits the invasion of HuH28 cells, we next tested the effect of AFU on the expression of two MMPs, MMP-2 and MMP-9, which are crucial to cellular invasion [17, 18]. Western blot analysis showed that AFU significantly decreased the expression of MMP-2 and MMP-9 in HuH28 cells (Figure 4). This data showed that the AFU likely diminished the capacity of invasion in HuH28 cells by downregulating their levels of MMP-2 and MMP-9.

4. Discussion

Our study highlights the significance of the preoperative serum AFU level for evaluating likely OS in patients with iCCA. In this study, the AFU level was confirmed to be an independent prognostic factor in patients with iCCA. By multivariate analysis, lymph node metastasis, CA19-9, and AFU level were associated with OS in iCCA patients. Moreover, AFU was shown to decrease the invasion capability of HuH28 cells by downregulating MMP-2 and MMP-9.

AFU, a lysosomal enzyme that hydrolyzes alpha-L-fucose by cleaving α-1,2, α-1,3, α-1,4, and α-1,6 linkages in the glycosylation chains is believed to be a tumor marker in the diagnosis of hepatic carcinoma and colorectal cancer [8, 9].

A recent study has shown that a higher preoperative serum AFU level was associated with poor outcomes in hepatic carcinoma, having a negative effect on prognosis [10]. However, other studies have shown that the level of AFU was higher in normal tissue than in tumor tissue and lower AFU levels were associated with poor prognosis in patients with breast cancer [9, 12, 19]. In this research, we firstly
Table 2: Univariate and multivariate analyses of factors affecting overall survival in patients with intrahepatic cholangiocarcinoma (iCCA).

| Characteristics          | Univariate                  |          |          |          |          |          |          |
|--------------------------|-----------------------------|----------|----------|----------|----------|----------|----------|
|                          | Hazard ratio (95% CI)       | P value  | Hazard ratio (95% CI) | P value  |          |          |          |
| Age (years)              |                             |          |          |          |          |          |          |
| <60                      | 1 (reference)               |          |          |          |          |          |          |
| ≥60                      | 0.978 (0.614–1.558)         | 0.925    | n.d.     | n.d.     |          |          |          |
| Gender                   |                             |          |          |          |          |          |          |
| Female                   | 1 (reference)               |          |          |          |          |          |          |
| Male                     | 1.464 (0.907–2.363)         | 0.119    | n.d.     | n.d.     |          |          |          |
| Lymph node metastasis    |                             |          |          |          |          |          |          |
| No                       | 1 (reference)               | <0.001   | 1 (reference) | 2.407 (1.435–4.037) | 0.001    |          |          |
| Yes                      | 2.746 (1.744–4.323)         |          |          |          |          |          |          |
| Tumor number             |                             |          |          |          |          |          |          |
| Solitary                 | 1 (reference)               |          |          |          |          |          |          |
| Multiple                 | 1.856 (1.191–2.893)         | 0.006    | NS       |          |          |          |          |
| Tumor size (cm)          |                             |          |          |          |          |          |          |
| ≤5                       | 1 (reference)               | <0.001   |          |          |          |          |          |
| >5                       | 2.210 (1.364–3.581)         | 0.001    | NS       |          |          |          |          |
| TNM stage                |                             |          |          |          |          |          |          |
| I                        | 1 (reference)               |          |          |          |          |          |          |
| II–IV                    | 3.542 (1.983–6.328)         |          |          |          |          |          |          |
| AFU (U/L)                |                             |          |          |          |          |          |          |
| <20.85                   | 1 (reference)               |          |          |          |          |          |          |
| ≥20.85                   | 0.596 (0.381–0.932)         | 0.023    | 1 (reference) | 0.526 (0.331–0.834) | 0.006    |          |          |
| CA19-9 (U/mL)            |                             |          |          |          |          |          |          |
| <100                     | 1 (reference)               | <0.001   |          |          |          |          |          |
| ≥100                     | 2.793 (1.786–4.368)         |          |          |          |          |          |          |
| ALT (U/L)                |                             |          |          |          |          |          |          |
| ≤40                      | 1 (reference)               |          |          |          |          |          |          |
| >40                      | 1.117 (0.678–1.839)         | 0.664    | n.d.     | n.d.     |          |          |          |
| AST (U/L)                |                             |          |          |          |          |          |          |
| ≤45                      | 1 (reference)               |          |          |          |          |          |          |
| >45                      | 0.608 (0.280–1.323)         | 0.210    | n.d.     | n.d.     |          |          |          |

CI: confidence interval; AST: aspartate transaminase; ALT: alanine aminotransferase; AFU: alpha-L-fucosidase; CA19-9: carbohydrate antigen 19-9; n.d.: not done; NS: no significance.

studied the prognostic effect of the serum AFU level on OS in iCCA patients. Because various cutoff values have been used when assessing the relationship between AFU level and OS in different cancers [10, 12], we used ROC curve analyses to verify the optimal cutoff point for AFU in this study. Patients with iCCA were therefore categorized into two groups: AFU level < 20.85 and ≥20.85 U/L. Using this cutoff, we found that AFU level is an independent prognostic factor in patients with iCCA by both univariate and multivariate analyses. Our results showed that a lower AFU level was associated with a poorer prognosis in patients with iCCA.

Large numbers of factors impact on the prognosis of patients with cancer. Tumor invasion is an important factor in cancer metastasis, which often ends in the death of the patient [13]. MMPs are zinc-dependent endopeptidases, which play important roles in tumor invasion by degrading collagen IV to destroy basement membrane [14]. Furthermore, MMP-2 has been shown to enhance the capacity of cellular invasion by interaction with αvβ3 integrin [20]. Similarly, MMP-9 also enhances cell migration and metastatic capacity by activating αvβ3 integrin [21]. Recent research showed that MMP-2 and MMP-9 were expressed in iCCA and participated in tumor invasion and metastasis [22–24]. Moreover, it has been reported that AFU was able to decrease the activity of MMP-9, therefore diminishing the invasive capability of breast cancer [11, 25].

In this study, we explored the effect of AFU on metastasis in an iCCA cell line using an invasion assay. As expected, our results showed that AFU could indeed inhibit the metastasis of the iCCA cell line. We also found that AFU downregulated the expression of MMP-2 and MMP-9. All of these results showed that AFU could impede the metastatic features of iCCA cells, explaining possibly how it may be associated with better OS of iCCA patients.

Even though AFU is an easily measurable parameter in clinical practice, there are several limitations in the present
Figure 3: Invasion assays were used to detect the motility of HuH28 cells treated with phosphate-buffered saline (PBS)/alpha-L-fucosidase (AFU)/AFU + deoxyfuconojirimycin (DFJ) for 30 minutes. The cells that invaded or migrated to the lower side were counted using a microscope. Original magnification of images shown: ×100. Differences in invasion between the groups were analyzed by the Mann–Whitney test. *P < 0.05.

In conclusion, the AFU level is an easily measurable biomarker that reflects prognosis in patients with iCCA. Preoperative AFU levels may help in predicting OS and guiding clinical management. As AFU was able to inhibit the invasion capacity of iCCA, further attempts should be made to explore the mechanism of downregulation of MMP-2 and MMP-9 induced by AFU and the best strategy involving AFU for iCCA treatment to prolong the survival of the patients with iCCA.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

Zeyu Shuang, Yize Mao, and Guohe Lin contributed equally to this work.

Acknowledgments

This study was supported by the National Natural Science Foundation of China (81171890).

Supplementary Materials

Supplementary Figure 1: the CCK8 assay was used to detect the viability of the HuH28 cell line after treatment with PBS/AFU/AFU + DFJ. (Supplementary Materials)
References

[1] S. A. Khan, H. C. Thomas, B. R. Davidson, and S. D. Taylor-Robinson, "Cholangiocarcinoma," The Lancet, vol. 366, no. 9493, pp. 1303–1314, 2005.

[2] H. B. El-Serag, E. A. Engels, O. Landgren et al., "Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: a population-based study of U.S. veterans," Hepatology, vol. 49, no. 1, pp. 116–123, 2009.

[3] I. Endo, M. Gonen, A. C. Yopp et al., "Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection," Annals of Surgery, vol. 248, no. 1, pp. 84–96, 2008.

[4] H. Mahli and G. J. Gores, "Cholangiocarcinoma: Modern advances in understanding a deadly old disease," Journal of Hepatology, vol. 45, no. 6, pp. 856–867, 2006.

[5] Y. H. Shaib, J. A. Davila, K. McGlynn, and H. B. El-Serag, "Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase?" Journal of Hepatology, vol. 40, no. 3, pp. 472–477, 2004.

[6] G. Spolverato, A. Vitale, A. Cucchetti et al., "Can hepatic resection provide a long-term cure for patients with intrahepatic cholangiocarcinoma?" Cancer, vol. 121, no. 22, pp. 3998–4006, 2015.

[7] M. C. de Jong, H. Nathan, G. C. Sotiropoulos et al., "Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment," Journal of Clinical Oncology, vol. 29, no. 10, pp. 3140–3145, 2011.

[8] Y. Deugnier, V. David, P. Brisset et al., "Serum α-L-Fucosidase: A New Marker for the Diagnosis of Primary Hepatic Carcinoma?" Hepatology, vol. 4, no. 5, pp. 889–892, 1984.

[9] M. DeLaCadena, J. Fernandez, A. deCarlos, V. MartinezZorzano, E. GilMartin, and F. RodriguezBerrocal, "Low levels of alpha-L-fucosidase activity in colorectal cancer are due to decreased amounts of the enzymatic protein and are related with Dukes' stage," International Journal of Oncology, vol. 9, pp. 747–754, 1996.

[10] K. Wang, W. Guo, N. Li et al., "Alpha-1-fucosidase as a prognostic indicator for hepatocellular carcinoma following heptatectomy: A large-scale, long-term study," British Journal of Cancer, vol. 110, no. 7, pp. 1811–1819, 2014.

[11] K. Yuan, C. M. Listinsky, R. K. Singh, J. J. Listinsky, and G. P. Siegal, "Cell surface associated alpha-1-fucose moieties modulate human breast cancer neoplastic progression," Pathology & Oncology Research, vol. 14, no. 2, pp. 145–156, 2008.

[12] T.-C. Cheng, S.-H. Tu, L.-C. Chen et al., "Down-regulation of α-L-fucosidase 1 expression confers inferior survival for triple-negative breast cancer patients by modulating the glycosylation status of the tumor cell surface," Oncotarget, vol. 6, no. 25, pp. 21283–21300, 2015.

[13] F. Han, L. Zhang, W. Qiu, and X. Yi, "TRAF6 promotes the invasion and metastasis and predicts a poor prognosis in gastric cancer," Pathology - Research and Practice, vol. 212, no. 1, pp. 31–37, 2016.

[14] W. G. Stetler-Stevenson, "The role of matrix metalloproteinases in tumor invasion, metastasis, and angiogenesis," Surgical Oncology Clinics of North America, vol. 10, pp. 383–392, 2001.

[15] S. B. Edge and C. C. Compton, "The american joint committee on cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM," Annals of Surgical Oncology, vol. 17, no. 6, pp. 1471–1474, 2010.

[16] A. M. Othman, M. E. El-Houseini, M. S. El-Sofi, and H. Y. Aboul-Enein, "Potentiometric determination of α-l-fucosidase enzyme by using 2-chloro-4-nitrophenol-rhodamine B ion pair chemical recognition in PVC membrane sensor," Analytical and Bioanalytical Chemistry, vol. 400, no. 3, pp. 787–795, 2011.

[17] E. I. Deryugina and J. P. Quigley, "Matrix metalloproteinases and tumor metastasis," Cancer and Metastasis Reviews, vol. 25, no. 1, pp. 9–34, 2006.

[18] M. Egeblad and Z. Werb, "New functions for the matrix metalloproteinases in cancer progression," Nature Reviews Cancer, vol. 2, no. 3, pp. 161–174, 2002.

[19] D. Ayude, M. P. De La Cadena, O. J. Cordero et al., "Clinical interest of the combined use of serum CD26 and alpha-L-fucosidase in the early diagnosis of colorectal cancer," Disease Markers, vol. 19, no. 6, pp. 267–272, 2003.

[20] P. C. Brooks, S. Strömblad, L. C. Sanders et al., "Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin αvβ3," Cell, vol. 85, no. 5, pp. 683–693, 1996.

[21] M. Rolli, E. Fransvea, J. Pilch, A. Saven, and B. Felding-Habermann, "Activated integrin αvβ3 cooperates with metalloproteinase MMP-9 in regulating migration of metastatic breast cancer cells," Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 16, pp. 9482–9487, 2003.

[22] H. Kirimlioglu, I. Turkmen, N. Bassullu, A. Dirican, N. Karadag, and V. Kirimlioglu, "The expression of matrix metalloproteinases in intrahepatic cholangiocarcinoma, hilar (Klatskin tumor), middle and distal extrahepatic cholangiocarcinoma, gallbladder cancer, and ampullary carcinoma: role of matrix metalloproteinases in tumor progression and prognosis," The Turkish Journal of Gastroenterology, vol. 20, pp. 41–47, 2009.

[23] R.-Y. Shi, X.-R. Yang, Q.-J. Shen et al., "High expression of Dickkopf-related protein 1 is related to lymphatic metastasis and indicates poor prognosis in intrahepatic cholangiocarcinoma patients after surgery," Cancer, vol. 119, no. 5, pp. 993–1003, 2013.

[24] K. Okamoto, K. Miyoshi, and Y. Murawaki, "miR-29b, miR-205 and miR-221 enhance chemosensitivity to gemcitabine in HuH28 human cholangiocarcinoma cells," PLoS ONE, vol. 8, no. 10, Article ID e76623, 2013.

[25] J. Conchic and A. J. Hay, "Mammalian glycosidases. 4. The intracellular localization of beta-galactosidase, alpha-mannosidase, beta-N-acetylgalcosaminidase and alpha-L-fucosidase in mammalian tissues," Biochemical Journal, vol. 87, pp. 354–361, 1963.